Clearmind Medicine's CMND-100 Meets Primary Endpoint in FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder
MWN-AI** Summary
Clearmind Medicine Inc. (Nasdaq: CMND) announced promising results from its FDA-approved Phase I/IIa clinical trial of CMND-100, a non-hallucinogenic drug candidate aimed at treating Alcohol Use Disorder (AUD). Conducted as a multinational, multicenter study, the trial's third cohort confirmed CMND-100's high safety profile and tolerability, even at higher doses, with no serious adverse events reported. This encouraging data fulfills the primary endpoint of safety and supports the continued development of CMND-100 as a potential therapeutic option for individuals suffering from moderate to severe AUD.
Clearmind Medicine specializes in the development of innovative neuroplastogen-derived therapeutics that address significant yet often neglected health issues through non-hallucinogenic psychedelic compounds. The company's intellectual property portfolio is robust, consisting of 19 patent families and 31 granted patents, with plans for further patent acquisitions as they explore additional opportunities in the field of AUD treatment and other areas.
Clearmind's management expressed optimism regarding the progress of their clinical trials, marking a significant step forward in the development of novel treatments for AUD. As a clinical-stage biotech company, Clearmind is committed to researching and commercializing psychedelic-based medicines, which could revolutionize the treatment landscape for conditions like AUD that currently have limited options available.
The announcement is significant not only for the company but also for the many individuals seeking effective treatments for Alcohol Use Disorder, potentially paving the way for more accessible and non-hallucinogenic alternatives in mental health care. Investors and stakeholders in Clearmind Medicine are encouraged to monitor the progress of ongoing trials as the company advances towards commercialization.
MWN-AI** Analysis
Clearmind Medicine Inc. (Nasdaq: CMND) has achieved a significant milestone by meeting the primary endpoint in its Phase I/IIa clinical trial for its non-hallucinogenic drug candidate, CMND-100, aimed at treating Alcohol Use Disorder (AUD). This promising outcome highlights the drug's high safety profile and favorable tolerability, even at higher dosages, reinforcing Clearmind's position in the growing biotech sector focused on innovative therapies.
Investors should view this positive news as a potential catalyst for a near-term market uptrend. The successful trial results bolster Clearmind's clinical credibility and could lead to heightened interest from institutional investors as well as a potential increase in retail trading volume. The absence of serious adverse events in the trial is particularly noteworthy, as it allays common safety concerns associated with new drug candidates, particularly in the field of psychotropics.
Moreover, Clearmind's intellectual property portfolio, consisting of 19 patent families and 31 granted patents, reinforces its competitive edge in the biotech space. As the company aims to commercialize its proprietary formulations, it is well-positioned to capitalize on the escalating demand for effective treatments for AUD and other mental health issues, which have gained increasing attention in recent years.
For prospective investors, Clearmind represents an attractive opportunity. As the company progresses through future trials, stakeholders should monitor upcoming data releases and regulatory developments closely, as they will be critical in shaping market perceptions and stock performance. Conversely, investors should remain aware of inherent risks, including market volatility and regulatory hurdles, especially in clinical trials.
In summary, Clearmind’s recent achievements and focus on a critical health challenge make its stock a potentially rewarding investment, provided one balances the associated risks with the promising growth trajectory ahead.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Vancouver, Canada, April 14, 2026 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems, today announced that CMND-100, the Company’s proprietary non-hallucinogenic MEAI-based oral drug candidate, for the treatment of Alcohol Use Disorder (AUD) has met the primary endpoint in its FDA-approved Phase I/IIa clinical trial.
Results from the third cohort of the trial indicated a high safety profile for CMND-100, even at the higher dosage administered to date. The data demonstrated that the drug candidate was well tolerated, with no serious adverse events reported in the third cohort and continued favorable overall tolerability, consistent with the safety outcomes observed in prior cohorts.
The Phase I/IIa clinical trial is a multinational, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD. Meeting the primary safety and tolerability endpoint in this dose-escalation stage, including at the higher dosage in the third cohort, supports continued advancement of CMND-100 as a potential novel, non-hallucinogenic treatment option for AUD.
About Clearmind Medicine Inc.
Clearmind is a clinical-stage neuroplastogens pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares of Clearmind are listed for trading on Nasdaq under the symbol "CMND."
For further information, visit: https://www.clearmindmedicine.com or contact:
Investor Relations
invest@clearmindmedicine.com
www.Clearmindmedicine.com
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the timing and progress of its clinical trials. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31, 2025 and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.
FAQ**
What are the potential implications of Clearmind Medicine Inc. CMND successfully achieving the primary endpoint in its Phase I/IIa trial for Alcohol Use Disorder on its future growth and market position?
How might the high safety profile of Clearmind Medicine Inc. CMND's CMND-100 drug influence investor confidence and market perception in the biotech sector?
In what ways could the results from Clearmind Medicine Inc. CMND's clinical trial contribute to advancements in non-hallucinogenic treatments for under-treated health issues?
What risks and uncertainties should investors consider regarding Clearmind Medicine Inc. CMND as it progresses through its clinical trial phases and seeks further patent protections?
**MWN-AI FAQ is based on asking OpenAI questions about Clearmind Medicine Inc. (NASDAQ: CMND).
NASDAQ: CMND
CMND Trading
41.04% G/L:
$3.53 Last:
41,970,858 Volume:
$3.49 Open:
